文献速递脑血管病外科神经重症

动脉内丹曲林治疗动脉瘤性蛛网膜下腔出血患者的难治性脑血管痉挛

Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2019-02-15

本文报告2例动脉瘤性蛛网膜下腔出血后难治性脑血管痉挛患者,经动脉内注射丹曲林15-30 mg后,受累血管管径即刻改善,平均动脉压与颅内压无显著变化,24小时内临床改善,48小时随访血管造影显示痉挛持续缓解。作者认为动脉内丹曲林是治疗脑血管痉挛安全有效的新型替代选择。

要点

  • 2例前交通动脉瘤破裂后难治性脑血管痉挛患者接受动脉内丹曲林15-30 mg治疗。
  • 注射后受累血管管径即刻改善,平均动脉压与颅内压无显著变化。
  • 48小时随访血管造影显示脑血管痉挛持续缓解。

核心结论

  • 作者认为动脉内丹曲林是治疗脑血管痉挛安全有效的新型替代选择。

研究设计与样本

  • 病例报告,共2例动脉瘤性蛛网膜下腔出血后难治性脑血管痉挛患者。

主要发现

  • 2例患者分别为63岁女性和36岁女性,前交通动脉瘤破裂后出现对动脉内血管扩张剂难治的严重血管痉挛。
  • 动脉内注射丹曲林15-30 mg后,受累血管分布区管径即刻改善。
  • 动脉内丹曲林注射前后平均动脉压和颅内压无显著差异。
  • 两例患者在24小时内均出现临床改善,住院剩余时间无进一步恶化。
  • 动脉内丹曲林治疗后48小时随访血管造影显示脑血管痉挛持续缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dantrolene has a safe side-effect profile and a mechanism of action that makes it attractive as an option for treatment of cerebral vasospasm. The authors report 2 cases of refractory cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage that were successfully treated with intra-arterial (IA) dantrolene. CASE DESCRIPTION: Two patients, a 63-year-old woman and 36-year-old woman, developed severe vasospasm refractory to IA vasodilators after rupture of anterior communicating artery aneurysms. IA dantrolene was injected in doses of 15-30 mg in the affected distributions and mean arterial pressure, intracranial pressure, and heart rate were monitored. There was immediate improvement in lumen diameter of the affected vessels following dantrolene injection. No significant differences in mean arterial pressure or intracranial pressure before and after IA dantrolene were observed. Both patients demonstrated clinical improvement within 24 hours without any further deterioration during the rest of their admission. Follow-up angiography 48 hours after IA dantrolene treatment demonstrated continued resolution of cerebral vasospasm. CONCLUSIONS: This evidence suggests IA dantrolene as a safe and effective novel alternative for the treatment of cerebral vasospasm.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ortiz Torres MJ, Jahngir M, Qualls K, et al. Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2019. PMID: 30776519. doi:10.1016/j.wneu.2019.01.239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。